Osteoporotic women with a history of vertebral fractures may be able toreduce the risk of additional vertebral fractures by taking salmon calcitonin nasally, according to a study presented at the ASBMR meeting.
The PROOF (Prevent Recurrence of Osteoporotic Fractures) study involved over 1,000 postmenopausal women with osteoporosis. The study found that patients receiving salmon calcitonin nasally were 37% less likely to develop new vertebral fractures than the control group. Following three years of treatment, Reuters reports, 12% of the women receiving active therapy had developed new vertebral fractures, against 20% of the placebo group.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze